Repositioning Candidate Details
| Candidate ID: | R0128 |
| Source ID: | DB00356 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Chlorzoxazone |
| Synonyms: | 2-hydroxy-5-chlorobenzoxazole; 5-chloro-2-benzoxazolinone; 5-chloro-2-benzoxazolol; 5-chloro-2-benzoxazolone; 5-chloro-2-hydroxybenzoxazole; 5-chloro-2(3H)-benzoxazolone; 5-chloro-3H-benzooxazol-2-one; 5-chlorobenzoxazolidone; 5-chlorobenzoxazolin-2-one; Chlorzoxane |
| Molecular Formula: | C7H4ClNO2 |
| SMILES: | ClC1=CC2=C(OC(=O)N2)C=C1 |
| Structure: |
|
| DrugBank Description: | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) |
| CAS Number: | 95-25-0 |
| Molecular Weight: | 169.565 |
| DrugBank Indication: | For the relief of discomfort associated with acute painful musculoskeletal conditions. |
| DrugBank Pharmacology: | Chlorzoxazone is a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex a.c. involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles. |
| DrugBank MoA: | Chlorzoxazone inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Chlorzoxazone also may reduce the release of inflammatory leukotrienes. Chlorzoxazone may act by inhibiting calcium and potassium influx which would lead to neuronal inhibition and muscle relaxation. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm |
| Targets: | Calcium-activated potassium channel subunit alpha-1 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|